Business
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of exper
About this update from Amgen Inc.
[{"type":"image","alt":"OMass Therapeutics","displaySize":"","headline":null,"caption":"OMass Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":175,"url":"https://media.zenfs.com/en/globenewswire.com/0f1756d1a5fac7497fc9c16e1ded8677"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tyYOlGGCAn5FafEBOX8iuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0f1756d1a5fac7497fc9c16e1ded8677","width":287,"height":175}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee","length":103,"tagName":"p"},{"type":"text","content":"Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.","length":344,"tagName":"p"},{"type":"text","content":"Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (Nasdaq: INSM), Immunome, Inc. (Nasdaq: IMNM), Kura Oncology, Inc (Nasdaq: KURA) and Repare Therapeutics Inc. (Nasdaq: RPTX). In addition, Carol previously served on the Board of Directors of Five Prime Therapeutics, Inc. (acquired by Amgen for $1.9 billion in April 2021) and Idera Pharmaceuticals, Inc. (until its merger in September 2022).","length":572,"tagName":"p"},{"type":"text","content":"From 2007 to 2018, Carol worked at Wells Fargo Securities in a variety of roles, including as Vice Chair, Equity Capital Markets. Prior to this, Carol worked at J.P. Morgan, where she held positions of increasing responsibility including Managing Director, Equity Capital Markets. She holds a Master of Business Administration from New York University’s Stern School of Business and a Bachelor of Arts from Boston College.","length":422,"tagName":"p"},{"type":"text","content":"“I am honoured to join the Board and contribute to the OMass’s mission of developing first or best-in-class s...